N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=46 Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Phase 2 N=20 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
N/A N=54 Diet and Physical Activity in Uterine Cancer Survivors
Endometrial Neoplasms
Primary: Recruitment Rate (Percentage of Potentially Eligible Participants Who Were Enrolled to the Study) — 20.3 percentage of participants
Phase 3 N=662 Endometrial Safety Study
Postmenopause
Primary: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) — 0 Participants
Phase 2 N=53 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 — 0; 0; 0; 3 Participants
Phase 2 N=28 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Endometrial Cancer · Recurrent Endometrial Cancer
Primary: Clinical Benefit Rate (CBR) — 7; 18 Participants
Phase 2 N=16 ZW25 in Women With Endometrial Cancers
Endometrial Cancer · Carcinosarcoma
Primary: Overall Response Rate/ORR of Participants — 1; 15 Participants
Phase 2 N=35 RAD001 in Recurrent Endometrial Cancer Patients
Endometrial Cancer
Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants
Phase 2 N=32 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients Completing the Protocol — 27 Participants
Phase 2 N=34 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events Occuring Within 90 Days After Treatment Start — 23.3 percentage of participants
Phase 2 N=28 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Adenocarcinoma
Primary: Response — 0 percentage of participants
Phase 2 N=27 A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Neoplasms · Neoplasms by Site · Urogenital Neoplasms
Primary: Tumor Response — 0; 1; 12; 11 participants
Phase 2 N=54 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants
N/A N=30 High Intensity Interval Training in Endometrial Cancer
Endometrial Cancer
Primary: Change in Proliferative Markers in Endometrium Before and After HIIT Exercises — 21.7; 15.1; 21.7; 20.2 Percentage of cells expressing Ki67
Phase 2 N=24 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 0 Participants
Phase 2 N=52 Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Recurrent Endometrial Carcinoma · Stage IV Endometrial Carcinoma
Primary: Tumor Response — 12 percentage of participants
Phase 2 N=35 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Progression-free Survival > 6 Months — 18.8 percentage of participants
Phase 2 N=30 A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
Uterine Cancer
Primary: 3-year Overall Survival — 17 partipants
Phase 2 N=33 Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Overall Disease Control Rate — 17 percentage of participants
Phase 2 N=56 Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 31; 21 participants
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Phase 2 N=37 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mucinous Adenocarcinoma
Primary: Number of Participants With Adverse Events — 1; 1; 2; 4 Participants